Roche to buy U.S. biotech firm InterMune for $8.3 bln

LONDON Sun Aug 24, 2014 12:25pm EDT

LONDON Aug 24 (Reuters) - Roche Holding AG has agreed to buy U.S. biotech company InterMune Inc for $8.3 billion in cash, marking the latest multibillion-dollar deal in a consolidating pharmaceutical sector, Roche said on Sunday.

The Swiss drugmaker will pay $74.00 a share for InterMune, representing a premium of 38 percent to the closing price on Aug. 22. (Reporting by Ben Hirschler, Editing by Angus MacSwan)

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.